These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 31943645)

  • 41. [Dulaglutide (Trulicity®), a new once-weekly agonist of glucagon-like peptide-1 receptors for type 2 diabetes].
    Scheen AJ
    Rev Med Liege; 2016 Mar; 71(3):154-60. PubMed ID: 27311248
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Improvement of glycaemic control and treatment satisfaction by switching from liraglutide or dulaglutide to subcutaneous semaglutide in patients with type 2 diabetes: A multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 1 study).
    Takahashi Y; Nomoto H; Yokoyama H; Takano Y; Nagai S; Tsuzuki A; Cho KY; Miya A; Kameda H; Takeuchi J; Taneda S; Kurihara Y; Atsumi T; Nakamura A; Miyoshi H;
    Diabetes Obes Metab; 2023 Jun; 25(6):1503-1511. PubMed ID: 36722623
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Lifetime Cost-effectiveness of Oral Semaglutide Versus Dulaglutide and Liraglutide in Patients With Type 2 Diabetes Inadequately Controlled With Oral Antidiabetics.
    Risebrough NA; Baker TM; Zhang L; Ali SN; Radin M; Dang-Tan T
    Clin Ther; 2021 Nov; 43(11):1812-1826.e7. PubMed ID: 34728099
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Predictors of response to glucagon-like peptide-1 receptor agonists: a meta-analysis and systematic review of randomized controlled trials.
    Monami M; Dicembrini I; Nreu B; Andreozzi F; Sesti G; Mannucci E
    Acta Diabetol; 2017 Dec; 54(12):1101-1114. PubMed ID: 28932989
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cutaneous hypersensitivity reaction to dulaglutide: A case report of an allergic reaction.
    Samhani C; Guerci B; Larose C
    Diabetes Metab; 2024 Sep; 50(5):101552. PubMed ID: 38942076
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Differential effects of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide and metformin on pancreatic β-cell and insulin sensitivity during a standardized test meal in patients with type 2 diabetes.
    Mari A; Del Prato S; Ludvik B; Milicevic Z; de la Peña A; Shurzinske L; Karanikas CA; Pechtner V
    Diabetes Obes Metab; 2016 Aug; 18(8):834-9. PubMed ID: 27059816
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of GLP-1 receptor agonists on myokine levels and pro-inflammatory cytokines in patients with type 2 diabetes mellitus.
    Guarnotta V; Bianco MJ; Vigneri E; Panto' F; Lo Sasso B; Ciaccio M; Pizzolanti G; Giordano C
    Nutr Metab Cardiovasc Dis; 2021 Oct; 31(11):3193-3201. PubMed ID: 34518091
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists.
    Madsbad S
    Diabetes Obes Metab; 2016 Apr; 18(4):317-32. PubMed ID: 26511102
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cost-effectiveness analysis of exenatide once-weekly versus dulaglutide, liraglutide, and lixisenatide for the treatment of type 2 diabetes mellitus: an analysis from the UK NHS perspective.
    Chuang LH; Verheggen BG; Charokopou M; Gibson D; Grandy S; Kartman B
    J Med Econ; 2016 Dec; 19(12):1127-1134. PubMed ID: 27310712
    [TBL] [Abstract][Full Text] [Related]  

  • 50. MANAGEMENT OF ENDOCRINE DISEASE: Are all GLP-1 agonists equal in the treatment of type 2 diabetes?
    Nauck MA; Meier JJ
    Eur J Endocrinol; 2019 Dec; 181(6):R211-R234. PubMed ID: 31600725
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A 24-week study to evaluate the efficacy and safety of once-weekly dulaglutide added on to glimepiride in type 2 diabetes (AWARD-8).
    Dungan KM; Weitgasser R; Perez Manghi F; Pintilei E; Fahrbach JL; Jiang HH; Shell J; Robertson KE
    Diabetes Obes Metab; 2016 May; 18(5):475-82. PubMed ID: 26799540
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Dulaglutide and liraglutide compared].
    Bruhn C
    Med Monatsschr Pharm; 2015 May; 38(5):198-9. PubMed ID: 26364414
    [No Abstract]   [Full Text] [Related]  

  • 53. Efficacy of dulaglutide on vascular health indexes in subjects with type 2 diabetes: a randomized trial.
    Tuttolomondo A; Cirrincione A; Casuccio A; Del Cuore A; Daidone M; Di Chiara T; Di Raimondo D; Corte VD; Maida C; Simonetta I; Scaglione S; Pinto A
    Cardiovasc Diabetol; 2021 Jan; 20(1):1. PubMed ID: 33397395
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Any expectations from the more powerful dulaglutide?].
    Škrha J
    Vnitr Lek; 2022; 68(2):124-126. PubMed ID: 36208927
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Addition of glucagon-like peptide-1 receptor agonist therapy to insulin in C-peptide-positive patients with type 1 diabetes.
    Kuhadiya ND; Prohaska B; Ghanim H; Dandona P
    Diabetes Obes Metab; 2019 Apr; 21(4):1054-1057. PubMed ID: 30536789
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
    Frias JP; Nauck MA; Van J; Kutner ME; Cui X; Benson C; Urva S; Gimeno RE; Milicevic Z; Robins D; Haupt A
    Lancet; 2018 Nov; 392(10160):2180-2193. PubMed ID: 30293770
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Low incidence of anti-drug antibodies in patients with type 2 diabetes treated with once-weekly glucagon-like peptide-1 receptor agonist dulaglutide.
    Milicevic Z; Anglin G; Harper K; Konrad RJ; Skrivanek Z; Glaesner W; Karanikas CA; Mace K
    Diabetes Obes Metab; 2016 May; 18(5):533-6. PubMed ID: 26847401
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Long-acting GLP-1RAs: An overview of efficacy, safety, and their role in type 2 diabetes management.
    Chun JH; Butts A
    JAAPA; 2020 Aug; 33(8):3-18. PubMed ID: 32740121
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cost Effectiveness of Dulaglutide Compared with Liraglutide and Glargine in Type 2 Diabetes Mellitus Patients in Colombia.
    Lasalvia P; Baquero L; Otálora-Esteban M; Castañeda-Cardona C; Rosselli D
    Value Health Reg Issues; 2017 Dec; 14():35-40. PubMed ID: 29254540
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The cost-effectiveness of dulaglutide versus insulin glargine for the treatment of type 2 diabetes mellitus in Japan.
    Ishii H; Madin-Warburton M; Strizek A; Thornton-Jones L; Suzuki S
    J Med Econ; 2018 May; 21(5):488-496. PubMed ID: 29357718
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.